LinkedIn Profile

Access Altheos historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:altheos 1923648 Dec 3rd, 2020 12:00AM Altheos 121 1.00 Open Pharmaceuticals Dec 3rd, 2020 08:49AM Dec 3rd, 2020 08:49AM Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. Open drug development (ocular diseases) Open 601 Gateway Boulevard.,, Suite 250 South San Francisco California US 94080 Altheos Health Care Equipment & Services
private:altheos 1923648 Dec 2nd, 2020 12:00AM Altheos 121 1.00 Open Pharmaceuticals Dec 2nd, 2020 11:11AM Dec 2nd, 2020 11:11AM Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. Open drug development (ocular diseases) Open 601 Gateway Boulevard.,, Suite 250 South San Francisco California US 94080 Altheos Health Care Equipment & Services
private:altheos 1923648 Dec 1st, 2020 12:00AM Altheos 121 1.00 Open Pharmaceuticals Dec 1st, 2020 09:47AM Dec 1st, 2020 09:47AM Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. Open drug development (ocular diseases) Open 601 Gateway Boulevard.,, Suite 250 South San Francisco California US 94080 Altheos Health Care Equipment & Services
private:altheos 1923648 Nov 30th, 2020 12:00AM Altheos 121 1.00 Open Pharmaceuticals Nov 30th, 2020 10:06AM Nov 30th, 2020 10:06AM Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. Open drug development (ocular diseases) Open 601 Gateway Boulevard.,, Suite 250 South San Francisco California US 94080 Altheos Health Care Equipment & Services
private:altheos 1923648 Nov 29th, 2020 12:00AM Altheos 121 1.00 Open Pharmaceuticals Nov 29th, 2020 04:52PM Nov 29th, 2020 04:52PM Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. Open drug development (ocular diseases) Open 601 Gateway Boulevard.,, Suite 250 South San Francisco California US 94080 Altheos Health Care Equipment & Services
private:altheos 1923648 Nov 28th, 2020 12:00AM Altheos 121 1.00 Open Pharmaceuticals Nov 28th, 2020 12:44PM Nov 28th, 2020 12:44PM Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. Open drug development (ocular diseases) Open 601 Gateway Boulevard.,, Suite 250 South San Francisco California US 94080 Altheos Health Care Equipment & Services
private:altheos 1923648 Nov 27th, 2020 12:00AM Altheos 121 1.00 Open Pharmaceuticals Nov 27th, 2020 09:04AM Nov 27th, 2020 09:04AM Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. Open drug development (ocular diseases) Open 601 Gateway Boulevard.,, Suite 250 South San Francisco California US 94080 Altheos Health Care Equipment & Services
private:altheos 1923648 Nov 26th, 2020 12:00AM Altheos 121 1.00 Open Pharmaceuticals Nov 26th, 2020 10:06AM Nov 26th, 2020 10:06AM Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. Open drug development (ocular diseases) Open 601 Gateway Boulevard.,, Suite 250 South San Francisco California US 94080 Altheos Health Care Equipment & Services
private:altheos 1923648 Nov 25th, 2020 12:00AM Altheos 121 1.00 Open Pharmaceuticals Nov 25th, 2020 12:22PM Nov 25th, 2020 12:22PM Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. Open drug development (ocular diseases) Open 601 Gateway Boulevard.,, Suite 250 South San Francisco California US 94080 Altheos Health Care Equipment & Services
private:altheos 1923648 Nov 24th, 2020 12:00AM Altheos 121 1.00 Open Pharmaceuticals Nov 24th, 2020 08:56AM Nov 24th, 2020 08:56AM Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. Open drug development (ocular diseases) Open 601 Gateway Boulevard.,, Suite 250 South San Francisco California US 94080 Altheos Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.